Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer

Inclusion Criteria: * Advanced epithelial Ovarian Cancer (stage IIB-IV) * Persistent or progressive disease after or relapse within one year of completion of first line therapy * Measurable or assessable disease * Eastern Cooperative Oncology Group status less than or equal to 2 Exclusion Criteria: * History of any other active malignancy * Signs of CNS metastasis * More than one prior chemotherapy regimen * Radiotherapy (bone) less than 4 weeks prior to start of treatment and radiotherapy (visceral) less than 8 weeks * First line chemotherapy completed at least 1 month prior to start of treatment